What is Tvardi Therapeutics, Inc. (TVRD) stock price today?

Tvardi Therapeutics, Inc. (TVRD) currently trades at $3.15 per share. The stock has a market capitalization of $30.02M and a P/E ratio of —x.

Is TVRD stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Tvardi Therapeutics, Inc. has a Smart Value Score of 26/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 4/9 and Altman Z-Score is -25.06.

Is Tvardi Therapeutics, Inc. financially healthy?

Tvardi Therapeutics, Inc.'s Piotroski F-Score is 4/9 (moderate financial health). The Altman Z-Score of -25.06 places it in the distress.

TVRD

Tvardi Therapeutics, Inc.

NASDAQ: TVRD · HEALTHCARE · BIOTECHNOLOGY

$3.15

+2.94% today

Updated 2026-04-30

Market cap

$30.02M

P/E ratio

—

P/S ratio

559.61x

EPS (TTM)

$-3.26

Dividend yield

—

52W range

$3 – $44

Volume

0.0M

Market cap

$30.02M

P/E ratio

—

P/S ratio

559.61x

EPS (TTM)

$-3.26

Dividend yield

—

52W range

$3 – $44

Volume

0.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.0

Quality

B+

3.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

-25.1

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$8.17

+159.37%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy4 Buy4 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.01x — low leverage

Risks

- Altman Z -25.06 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-5.68M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$41.87M	$20.97M	$7.14M	$0.00	$0.00
Net income	$-85.47M	$-118.51M	$-70.87M	$-18.21M	$-7.28M
EPS	—	—	—	—	$-3.26
Free cash flow	$-17.92M	$-23.41M	$-61.96M	$-23.50M	$-5.68M
Profit margin	-204.16%	-565.21%	-992.95%	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
TVRD	$30.02M	26	4.3	3.0	5.0	7.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Tvardi Therapeutics, Inc. trades at $3.15. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -25.06, it sits in the distress.

Frequently asked questions

What is Tvardi Therapeutics, Inc.'s stock price?

Tvardi Therapeutics, Inc. (TVRD) trades at $3.15.

Is Tvardi Therapeutics, Inc. overvalued?

Smart Value Score 26/100 (Grade F, Strong Sell).

What is the price target of Tvardi Therapeutics, Inc. (TVRD)?

The analyst target price is $8.17, representing +159.4% upside from the current price of $3.15.

Piotroski F-Score?

4/9 — moderate financial health.

Altman Z-Score?

-25.06 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

tvarditherapeutics.com

Quick metrics

P/S ratio559.61x

ROE-237.80%

Beta—

50D MA$3.46

200D MA$12.56

Shares out0.01B

Float0.01B

Short ratio—

Avg volume0.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

TVRD vs LLY →TVRD vs JNJ →TVRD vs ABBV →Stock screener →